Document is current
Any future updates will be listed below
-
Authors
Fraser, Heather L. https://orcid.org/0000-0002-7100-571X
Haag, Laura https://orcid.org/0000-0003-3342-1365
Brosnahan, Naomi
McConnachie, Alex https://orcid.org/0000-0002-7262-7000
Richardson, Janice
Haig, Caroline E.
Ibbotson, Tracy https://orcid.org/0000-0002-9224-6467
Ormerod, Jane
O’Donnell, Catherine A.
Lean, Michael E. J. https://orcid.org/0000-0003-2216-0083
Sattar, Naveed https://orcid.org/0000-0002-1604-2593
Blane, David N. https://orcid.org/0000-0002-3872-3621
Combet, Emilie
McIntosh, Emma
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (COV-LT2-0059)
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 2 May 2025
First Online: 1 July 2025
Competing interests
: N.B. is an employee and shareholder of Counterweight Ltd., subcontracted to the University of Glasgow to deliver the ReDIRECT intervention. A.M. is a member of Clinical Steering Committee for ARC Medical Inc. N.S. has received institutional grant support from AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics and honoraria from Abbott Laboratories, AbbVie, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-Ricerche, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, Sanofi. M.L. has received lecturing fees from Novo Nordisk, Lilly, Nestle, Oviva, Merck, and Sanofi and is a medical advisor to Counterweight Ltd, with fees paid to the University of Glasgow. The remaining authors declare no competing interests.
